
Complaints have been filed on behalf of
women who have suffered heart attacks, strokes, Yaz pulmonary embolism, deep vein
thrombosis and other
serious blood clot-related injuries, which they allege may
have been prevented if more adequate information about the Yasmin and Yaz blood
clot risk had been provided. Initial data from the FDA-funded epidemiologic
study involving 800,000 women that is exploring the association of blood clots
with several different hormonal contraceptive products, including
levonorgestrel-containing contraceptives, appear consistent with conclusions
from the 2009 and 2011 published studies, finding a 1.5-fold increase risk for
blood clots among women taking contraceptives with drospirenone.
Yaz
(droperinone & ethinyl estradiol) is a once-a-day birth control pill that
was first approved by the FDA in March 2006 to prevent unwanted
pregnancy. In October 2006, approval was expanded to include treatment of
the emotional and physical symptoms of premenstrual dysphoric disorder (PMDD),
which is a more severe version of PMS that interferes with daily activities.
In January 2007, it was also approved to treat moderate acne in women who
already desire birth control. About 6,350 cases of Yasmin and Yaz lawsuits are now consolidated as part of the litigation before Judge Herndon in the U.S.
District Court for the Southern District of Illinois. When Judge Herndon
implemented the original bellwether program in October 2010, there were about
3,700 filed cases and the number of cases is expected to continue to grow as Yaz and Yasmin lawyers review
and file additional cases.
No comments:
Post a Comment